A compound of formula: wherein, R A is selected from the group consisting of C 1-10 alkyl, C 3-10 cycloalkyl and C 5-10 spirocycloalkyl; wherein R A is not substituted or is substituted by one or more substituents selected from the group consisting of oxo, R 1A, OR 2A, NR 2A R 3A, SR 2A, SOR 9A, SO 2 R 9A, SO 2 NR 2A R 3A, C R 2A and CONR 2A R 3A; R 1A is selected from the group consisting of fluoro, methyl, cyano, SiR 4A R 5A R 6A, C 3-8 cycloalkyl and phenyl; wherein methyl, C 3-8 cycloalkyl and phenyl are not substituted or are substituted by R 7A and/or R 8A; R 4A, R 5A and R 6A are independently selected from the group consisting of C 1-4 alkyl and phenyl; R 7A and R 8A are independently selected from the group consisting of oxo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, hydroxy, CO 2 H, cyano, methanesulfonyl and halo; or, taken together, R 7A and R 8A form a C 3-8 cycloalkyl or 4-7 membered heterocyclic ring; R 2A and R 3A are independently H, C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; or, taken together, R 2A and R 3A form a 4-7 membered heterocyclic ring; R 9A is C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; and R B is C 1-2 alkyl substituted by CO 2 H and is optionally further substituted by trifluoromethyl or methyl; R C and R D are independently selected from the group consisting of H, C 1-2 alkyl, hydroxy, methoxy and fluoro; or a pharmaceutically acceptable salt and/or solvate thereof. R A is selected from the group consisting of C 1-10 alkyl, C 3-10 cycloalkyl and C 5-10 spirocycloalkyl; wherein R A is not substituted or is substituted by one or more substituents selected from the group consisting of oxo, R 1A, OR 2A, NR 2A R 3A, SR 2A, SOR 9A, SO 2 R 9A, SO 2 NR 2A R 3A, C R 2A and CONR 2A R 3A; R 1A is selected from the group consisting of fluoro, methyl, cyano, SiR 4A R 5A R 6A, C 3-8 cycloalkyl and phenyl; wherein methyl, C 3-8 cycloalkyl and phenyl are not substituted or are substituted by R 7A and/or R 8A; R 4A, R 5A and R 6A are independently selected from the group consisting of C 1-4 alkyl and phenyl; R 7A and R 8A are independently selected from the group consisting of oxo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, hydroxy, CO 2 H, cyano, methanesulfonyl and halo; or, taken together, R 7A and R 8A form a C 3-8 cycloalkyl or 4-7 membered heterocyclic ring; R 2A and R 3A are independently H, C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; or, taken together, R 2A and R 3A form a 4-7 membered heterocyclic ring; R 9A is C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; and R 1A is selected from the group consisting of fluoro, methyl, cyano, SiR 4A R 5A R 6A, C 3-8 cycloalkyl and phenyl; wherein methyl, C 3-8 cycloalkyl and phenyl are not substituted or are substituted by R 7A and/or R 8A; R 4A, R 5A and R 6A are independently selected from the group consisting of C 1-4 alkyl and phenyl; R 7A and R 8A are independently selected from the group consisting of oxo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, hydroxy, CO 2 H, cyano, methanesulfonyl and halo; or, taken together, R 7A and R 8A form a C 3-8 cycloalkyl or 4-7 membered heterocyclic ring; R 4A, R 5A and R 6A are independently selected from the group consisting of C 1-4 alkyl and phenyl; R 7A and R 8A are independently selected from the group consisting of oxo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, hydroxy, CO 2 H, cyano, methanesulfonyl and halo; or, taken together, R 7A and R 8A form a C 3-8 cycloalkyl or 4-7 membered heterocyclic ring; R 2A and R 3A are independently H, C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; or, taken together, R 2A and R 3A form a 4-7 membered heterocyclic ring; R 9A is C 1-8 alkyl, C 3-8 cycloalkyl or phenyl; and R B is C 1-2 alkyl substituted by CO 2 H and is optionally further substituted by trifluoromethyl or methyl; R C and R D are independently selected from the group consisting of H, C 1-2 alkyl, hydroxy, methoxy and fluoro; or a pharmaceutically acceptable salt and/or solvate thereof.